Polar Capital Holdings Plc Trims Stock Position in Qiagen (NYSE:QGEN)

Polar Capital Holdings Plc trimmed its holdings in Qiagen (NYSE:QGEN) by 29.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 170,863 shares of the company’s stock after selling 69,621 shares during the quarter. Polar Capital Holdings Plc owned approximately 0.08% of Qiagen worth $7,609,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of QGEN. Quantinno Capital Management LP boosted its position in Qiagen by 45.8% during the fourth quarter. Quantinno Capital Management LP now owns 114,774 shares of the company’s stock valued at $5,114,000 after purchasing an additional 36,067 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Qiagen by 31.6% in the fourth quarter. Parkman Healthcare Partners LLC now owns 277,272 shares of the company’s stock worth $12,347,000 after acquiring an additional 66,503 shares during the last quarter. Man Group plc boosted its stake in shares of Qiagen by 17.6% in the fourth quarter. Man Group plc now owns 483,357 shares of the company’s stock worth $21,524,000 after acquiring an additional 72,239 shares during the last quarter. OMERS ADMINISTRATION Corp increased its stake in Qiagen by 37.8% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 12,400 shares of the company’s stock worth $552,000 after acquiring an additional 3,400 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Qiagen by 3.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 170,957 shares of the company’s stock worth $7,613,000 after acquiring an additional 5,681 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Up 2.5%

Qiagen stock opened at $42.19 on Friday. The firm has a market capitalization of $9.38 billion, a PE ratio of 117.48, a P/E/G ratio of 2.39 and a beta of 0.67. The company’s 50-day moving average is $40.90 and its 200-day moving average is $41.79. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $0.44 earnings per share. Sell-side analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of recent research reports. Baird R W lowered Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. UBS Group cut their target price on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Redburn Atlantic downgraded Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Robert W. Baird raised their price objective on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. Finally, StockNews.com upgraded Qiagen from a “buy” rating to a “strong-buy” rating in a report on Thursday. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Qiagen has a consensus rating of “Hold” and a consensus price target of $48.42.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.